Compare Alcon AG (ALC) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs First Citizens BancShares Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while First Citizens BancShares Inc trades at $2,045.06 (market cap $23.94B). The key difference: Alcon AG is the larger of the two by market cap, and Alcon AG pays the higher dividend (0.54%). Which is the better fit depends on your goals.
| ALC | FCNCA | |
|---|---|---|
Market Cap | $32.69B | $23.94B |
Sector | Health | Sector/Thematic |
52-Week High | $92.22 | $2.20K |
52-Week Low | $62.02 | $1.64K |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
First Citizens BancShares (FCNCA) trades at $2,117.35, up 1.65% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamental health with a P/E of 12.21 and net income margin of 24.35%, supported by consecutive earnings beats including Q1 2026 EPS of $44.86 versus $39.56 expected. Recent corporate developments include the planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.
The outlook remains positive given earnings momentum and analyst consensus price target of $2,320, though risks include margin pressure and credit exposure from the SVB integration. Upside potential hinges on continued execution amid a competitive banking landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
